RenovoRx, Inc. RNXT
RenovoRx, Inc. (Nasdaq: RNXT) is an oncology drug developer. Its lead program, IAG (intra-arterial gemcitabine delivered via RenovoCath, TAMP platform), is in Phase 3 for locally advanced pancreatic cancer (LAPC). Its next catalyst on record is IAG (TIGeR-PaC): Completion of Phase III trial after 86 events (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IAG (TIGeR-PaC) — Completion of Phase III trial after 86 events (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IAG (intra-arterial gemcitabine via RenovoCath) - TIGeR-PaC | locally advanced pancreatic cancer | device-combination | Phase 3 |
| Intra-arterial oxaliplatin (orphan designation Q2 2026) | pancreatic cancer | device-combination | Pre-clinical |
| RenovoCath (FDA 510(k)-cleared device, standalone commercial sales) | temporary vessel occlusion / chemotherapeutic drug infusion | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Aug 12, 2026completed enrollment TIGeR-PaC Phase 3 reached full enrollment; investigators notified Aug 7, 2026 that enrollment is closing; 78 of 86 required events observed.
Recently, RenovoRx announced that it achieved full enrollment in its Phase III TIGeR-PaC trial evaluating intra-arterial delivery of intra-arterial gemcitabine (IAG) via the RenovoCath device for the treatment of LAPC.
Filing - Aug 12, 2026n/a FDA Orphan Drug Designation received for oxaliplatin in pancreatic cancer in Q2 2026.
RenovoRx received FDA Orphan Drug Designation for oxaliplatin in the treatment of pancreatic cancer in the second quarter of 2026, further expanding the potential applications of its targeted drug-delivery platform.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.